共 11 条
- [1] Potent activation of dopamine D3/D2heterodimers by the antiparkinsonian a-gents,S32504,pramipexole and ropinirole. Maggio R,Scarselli M,Novi F,et al. Journal of Neurochemistry . 2003
- [2] Pramipexole in levodopa-treated Par-kinson disease patients of AfricanAsian,and Hispanic heritage. Parkison Study Group. Clinical Neuropharmacology . 2007
- [3] Effects of the dopamine ago-nist pramipexole on depression,anhedonia and motor functioning in Parkinson‘s disease. Lemke MR,Brecht HM,Koester Jet al. Journal of the Neurological Sciences . 2006
- [4] Levodopa induces a cytoplasmic localization of Dl dopamine receptors in striatal neurons in Parkinson‘s disease. Muriel MP,Bernard V,Levey AI,Laribi O,Abrous DN,Agid Y,Bloch B,Hirsch EC. Annals of Neurology . 1999
- [5] New pharm acotherapy for Parkinson s disease. Gottwald M D,Bainbridge JL,Dowling GA,etal. Annals of Pharmacotherapy . 1997
- [6] Long-term efficacy and safety of pramipexole in advanced Parkinson’s disease: results from a European multicenter trial. Moller JC,Oertel WH,Koster J,et al. Movement Disorders . 2005
- [7] Science,medicine and the future:Parkinson s disease. Schapira AH. British Medical Journal . 1999
- [8] Biochemical and pharmacological studies on pramipexole,a potent and selective dopamine D2 receptor agonist. Mieran J,Schingnitz G. European Journal of Pharmacology . 1992